Clinical-stage oncology developer of misetionamide (GP-2250), a small-molecule antineoplastic targeting platinum-resistant ovarian cancer. Inhibits oncogenic transcription factors c-MYC and NFκB to disrupt cancer cell energy metabolism, induce tumor cell death, and reduce proliferation/survival signaling.